These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734 [TBL] [Abstract][Full Text] [Related]
6. Brain neuropeptides in progressive supranuclear palsy. Taquet H; Javoy-Agid F; Mauborgne A; Benoliel JJ; Agid Y; Legrand JC; Hamon M; Cesselin F Brain Res; 1987 May; 411(1):178-82. PubMed ID: 2440513 [TBL] [Abstract][Full Text] [Related]
7. Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy. Ma JH; Dong C; Qiao HW; Barret O; Tamagnan GD; Mao W; Xu EH; Zhang C; Lu J; Chan P; Liu SY Mov Disord; 2024 May; 39(5):847-854. PubMed ID: 38477228 [TBL] [Abstract][Full Text] [Related]
8. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. Chinaglia G; Alvarez FJ; Probst A; Palacios JM Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470 [TBL] [Abstract][Full Text] [Related]
9. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073 [TBL] [Abstract][Full Text] [Related]
10. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242 [TBL] [Abstract][Full Text] [Related]
11. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy. Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779 [TBL] [Abstract][Full Text] [Related]
12. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. Im JH; Chung SJ; Kim JS; Lee MC J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371 [TBL] [Abstract][Full Text] [Related]
13. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742 [TBL] [Abstract][Full Text] [Related]
14. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429 [TBL] [Abstract][Full Text] [Related]
15. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890 [TBL] [Abstract][Full Text] [Related]
16. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia. Chinaglia G; Probst A; Palacios JM Neuroscience; 1990; 39(2):351-60. PubMed ID: 1965015 [TBL] [Abstract][Full Text] [Related]
17. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Henderson JM; Carpenter K; Cartwright H; Halliday GM Brain; 2000 Jul; 123 ( Pt 7)():1410-21. PubMed ID: 10869053 [TBL] [Abstract][Full Text] [Related]
18. Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease. Villares J; Strada O; Faucheux B; Javoy-Agid F; Agid Y; Hirsch EC Neurosci Lett; 1994 Nov; 182(1):59-62. PubMed ID: 7891888 [TBL] [Abstract][Full Text] [Related]
19. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Messa C; Volonté MA; Fazio F; Zito F; Carpinelli A; d'Amico A; Rizzo G; Moresco RM; Paulesu E; Franceschi M; Lucignani G Eur J Nucl Med; 1998 Sep; 25(9):1270-6. PubMed ID: 9724376 [TBL] [Abstract][Full Text] [Related]
20. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]